In a first, Intellia, Regeneron demonstrate CRISPR therapy benefit in the body

Intellia Therapeutics and Regeneron Pharmaceuticals have released interim data from a phase 1 trial of a CRISPR candidate showing that it was able to genetically edit liver cells.
Read More